Experimental Study of Tumor Therapy Mediated by Multimodal Imaging Based on a Biological Targeting Synergistic Agent.
Animals
Bifidobacterium longum
Coloring Agents
/ chemistry
Drug Delivery Systems
Female
Fluorocarbons
/ chemistry
High-Intensity Focused Ultrasound Ablation
/ methods
Human Umbilical Vein Endothelial Cells
Humans
Indocyanine Green
/ chemistry
Mice, Inbred BALB C
Microbubbles
Multimodal Imaging
/ methods
Nanoparticles
/ administration & dosage
Neoplasms
/ diagnostic imaging
Xenograft Model Antitumor Assays
fluorescence imaging
high-intensity focused ultrasound
image-guided therapy
nanoparticles
photoacoustic imaging
ultrasound imaging
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
11
2019
accepted:
24
02
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
28
7
2020
Statut:
epublish
Résumé
The high-intensity focused ultrasound (HIFU) ablation of tumors is inseparable from synergistic agents and image monitoring, but the existing synergistic agents have the defects of poor targeting and a single imaging mode, which limits the therapeutic effects of HIFU. The construction of a multifunctional biological targeting synergistic agent with high biosafety, multimodal imaging and targeting therapeutic performance has great significance for combating cancer. Multifunctional biological targeting synergistic agent consisting of Both in vitro and in vivo systematical studies validated that the biological targeting synergistic agent can simultaneously achieve tumor-biotargeted multimodal imaging, HIFU synergism and multimodal image monitoring in HIFU therapy. Importantly, the electrostatic adsorption method and the targeting of In this work, a biological targeting synergistic agent was successfully constructed with good stability and physicochemical properties. This biological targeting synergistic agent can not only provide information for early diagnosis of tumors but also realize multimodal imaging monitoring during HIFU ablation simultaneously with HIFU treatment, which improves the shortcomings of HIFU treatment and has broad application prospects.
Identifiants
pubmed: 32256065
doi: 10.2147/IJN.S238398
pii: 238398
pmc: PMC7085950
doi:
Substances chimiques
Coloring Agents
0
Fluorocarbons
0
perflexane
FX3WJ41CMX
Indocyanine Green
IX6J1063HV
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1871-1888Informations de copyright
© 2020 Wang et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
ACS Appl Mater Interfaces. 2019 Oct 9;11(40):36324-36332
pubmed: 31556582
Theranostics. 2014 Aug 01;4(10):1026-38
pubmed: 25161702
J Cancer Res Ther. 2010 Oct-Dec;6(4):414-20
pubmed: 21358073
J Gastroenterol Hepatol. 2007 Dec;22(12):2148-54
pubmed: 18031373
Cancer Sci. 2003 Dec;94(12):1021-8
pubmed: 14662015
Appl Phys Lett. 2014 Feb 10;104(6):063703
pubmed: 24711671
Radiol Med. 2011 Aug;116(5):734-48
pubmed: 21293939
Radiology. 2016 Aug;280(2):332-49
pubmed: 27429141
Adv Exp Med Biol. 2016;880:3-20
pubmed: 26486329
Ann Surg Oncol. 2004 Dec;11(12):1061-9
pubmed: 15545506
Nanoscale. 2016 Feb 21;8(7):4324-39
pubmed: 26837265
Int J Mol Sci. 2016 Jun 06;17(6):
pubmed: 27275821
Med Sci Monit. 2019 Apr 07;25:2553-2560
pubmed: 30955023
Onco Targets Ther. 2019 Feb 01;12:1021-1029
pubmed: 30774386
Medicine (Baltimore). 2019 Mar;98(10):e14566
pubmed: 30855440
J BUON. 2019 Mar-Apr;24(2):826-831
pubmed: 31128042
Adv Drug Deliv Rev. 2002 Sep 13;54(5):631-51
pubmed: 12204596
Appl Microbiol Biotechnol. 2012 Jul;95(2):499-509
pubmed: 22639142
Int J Urol. 2012 Mar;19(3):187-201
pubmed: 22188161
Nat Med. 2002 Jul;8(7):757-60
pubmed: 12091907
IEEE Trans Biomed Eng. 2019 Dec;66(12):3330-3338
pubmed: 30869607
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
pubmed: 9539785
Nat Rev Cancer. 2005 Apr;5(4):321-7
pubmed: 15776004
Methods Mol Biol. 2016;1409:49-60
pubmed: 26846801
Int J Pharm. 2015 Dec 30;496(2):173-90
pubmed: 26522982
Sci Rep. 2019 Apr 23;9(1):6423
pubmed: 31015517
Biochem Biophys Res Commun. 2019 Jul 5;514(4):1147-1153
pubmed: 31103266
J Cancer Res Ther. 2019;15(4):831-835
pubmed: 31436239
Sci Rep. 2018 Aug 30;8(1):13062
pubmed: 30166607
J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S
pubmed: 18523069
Ultrason Sonochem. 2018 Jul;45:57-64
pubmed: 29705325
Biomaterials. 2015 Jun 20;64:1
pubmed: 26100937
Cancer Gene Ther. 2000 Feb;7(2):269-74
pubmed: 10770636
Mol Pharm. 2019 Oct 7;16(10):4104-4120
pubmed: 31517495
Cardiovasc Intervent Radiol. 2013 Oct;36(5):1190-203
pubmed: 23474917
Ultrasound Med Biol. 2012 Apr;38(4):619-25
pubmed: 22342688
PLoS One. 2019 May 14;14(5):e0216926
pubmed: 31086403
Biomed Res Int. 2013;2013:404361
pubmed: 24350267
Ann Chir. 2003 Feb;128(1):18-25
pubmed: 12600324
J Control Release. 2016 Feb 28;224:217-228
pubmed: 26739551
Cancer Gene Ther. 2005 Feb;12(2):133-40
pubmed: 15565182
Cancer Gene Ther. 2012 Nov;19(11):731-40
pubmed: 22996740
Int J Pharm. 2016 Feb 29;499(1-2):358-367
pubmed: 26795193
Int J Nanomedicine. 2019 Jan 11;14:519-529
pubmed: 30666111
Diagn Interv Imaging. 2018 Jun;99(6):349-359
pubmed: 29778401
Diagn Interv Radiol. 2019 Sep;25(5):398-409
pubmed: 31287428
Int J Hyperthermia. 2019;36(1):768-775
pubmed: 31431150
Int J Nanomedicine. 2018 Apr 20;13:2405-2426
pubmed: 29719390